Screening of HER2 Overexpressed Breast Cancer Subtype In Vivo by the Validation of High-Performance, Long-Term, and Noninvasive Fluorescence Tracer
Screening of HER2 Overexpressed Breast Cancer Subtype In Vivo by the Validation of High-Performance, Long-Term, and Noninvasive Fluorescence Tracer
复制标题
通过高性能、长期、无创荧光示踪剂的验证在体内筛查 HER2 过表达乳腺癌亚型
DOI：
10.1021/acs.analchem.5b03580
复制
发表时间：
2015-12-15
影响因子：
7.4
通讯作者：
Zhu，Jun-Jie
中科院分区：
文献类型：
--
作者：
Ding，Jie;Zhou，Ying;Zhu，Jun-Jie
体内异质性肿瘤亚型的高性能和非侵入性筛选对于癌症的诊断和对症治疗是特别期望的。因此，我们报告了一种近红外（NIR）荧光示踪剂“智能识别HER 2”（SI-HER 2），用于快速，准确和高度特异性地筛查HER 2过表达的乳腺癌。通过聚组氨酸驱动的自组装方法将针对HER 2蛋白受体的抗体EP 1045 Y与发射NIR的CdSeTe/CdS/ZnS量子点缀合。黑洞猝灭剂3在抗体上的进一步吸附使得荧光示踪剂对HER 2蛋白受体的荧光响应能够“开启”。除了能够区分HER 2过表达的MCF-7细胞与其对应物之外，荧光示踪剂还可以准确快速地识别两种荷瘤小鼠模型中HER 2过表达的乳腺肿瘤亚型，为研究区分不同乳腺癌亚型的先进途径提供平台。
The high-performance and noninvasive screening of heterogeneous tumor subtypes in vivo is particularly desirable for the diagnosis and symptomatic treatment of cancer. Therefore, we report a near-infrared (NIR) fluorescence tracer "smartly identified HER2" (SI-HER2) for rapid, accurate, and highly specific screening of HER2 overexpressed breast cancer. An antibody against HER2 protein receptor, EP1045Y, was conjugated with NIR emitting CdSeTe/CdS/ZnS QDs via polyhistidine-driven self-assembly approach. The further adsorption of black hole quencher 3 on antibody enabled a "turn on" fluorescence response of the fluorescence tracer to HER2 protein receptor. Aside from the capability of differentiating the HER2 overexpressed MCF-7 cells from its counterparts, the fluorescence tracer can also accurately and rapidly identify the HER2 overexpressed breast tumor subtype in two tumors-bearing mouse model, providing a platform for the investigation of advanced pathways to distinguish the different breast cancer subtypes.